Wilson Therapeutics AB

AMiLion AB

This company develops a nanopore-based sensor platform that measures bioavailable copper levels in body fluids for patients with Alzheimer's, Wilson's, and Menkes diseases.

Acumen Pharmaceuticals

This biopharmaceutical company develops novel targeted therapies for patients with Alzheimer's disease by targeting toxic soluble amyloid beta oligomers.

Abliva

This biopharmaceutical company develops novel medicines for patients suffering from rare and severe primary mitochondrial diseases.

Vico Therapeutics

This company develops antisense oligonucleotide therapies to treat patients with rare genetic neurological disorders, including Huntington's disease and spinocerebellar ataxias.

Sentynl Therapeutics

Sentynl Therapeutics develops and provides pharmaceutical products, including copper histidinate, for patients living with rare diseases.

Yumanity Therapeutics

This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.

OxThera AB

This biopharmaceutical company develops bacteria-based therapies to treat patients with primary hyperoxaluria and other rare kidney diseases.

Alzinova

This biopharmaceutical company develops immunotherapies and vaccines targeting toxic amyloid-beta oligomers to treat and prevent Alzheimer's disease for patients worldwide.